Maze Therapeutics (NASDAQ:MAZE) Given New $51.00 Price Target at JPMorgan Chase & Co.

Maze Therapeutics (NASDAQ:MAZE) had its target price cut by equities research analysts at JPMorgan Chase & Co. from $53.00 to $51.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 37.52% from the stock’s current price.

A number of other equities analysts have also recently commented on the company. Citigroup started coverage on Maze Therapeutics in a report on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 target price on the stock. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Wedbush upped their price target on Maze Therapeutics from $48.00 to $49.00 and gave the stock an “outperform” rating in a research report on Tuesday. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Tuesday, September 22nd. Finally, Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Three analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $63.91.

Maze Therapeutics Stock Performance

MAZE stock traded up $1.64 during midday trading on Wednesday, reaching $37.09. 122,243 shares of the company’s stock traded hands, compared to its average volume of 671,773. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics has a 52-week low of $21.95 and a 52-week high of $53.65. The stock has a market cap of $2.06 billion, a P/E ratio of -14.02 and a beta of 2.04. The stock’s 50-day moving average is $28.12 and its 200 day moving average is $31.67.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.01). As a group, analysts anticipate that Maze Therapeutics will post -2.70 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Jason Coloma sold 34,501 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $26.29, for a total value of $907,031.29. Following the completion of the sale, the chief executive officer directly owned 18,151 shares of the company’s stock, valued at $477,189.79. This represents a 65.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $27.58, for a total transaction of $206,850.00. Following the sale, the insider owned 26,250 shares in the company, valued at $723,975. The trade was a 22.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 192,991 shares of company stock worth $5,187,559 over the last three months. 5.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of MAZE. Bessemer Group Inc. lifted its position in shares of Maze Therapeutics by 3.0% in the third quarter. Bessemer Group Inc. now owns 496,253 shares of the company’s stock valued at $13,488,000 after acquiring an additional 14,463 shares in the last quarter. Jefferies Financial Group Inc. bought a new position in shares of Maze Therapeutics in the third quarter worth about $1,519,000. Alps Advisors Inc. grew its position in shares of Maze Therapeutics by 31.5% during the third quarter. Alps Advisors Inc. now owns 73,574 shares of the company’s stock worth $2,000,000 after purchasing an additional 17,604 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Maze Therapeutics during the third quarter worth about $77,000. Finally, Profund Advisors LLC grew its position in shares of Maze Therapeutics by 410.5% during the third quarter. Profund Advisors LLC now owns 56,281 shares of the company’s stock worth $1,530,000 after purchasing an additional 45,256 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets. The company’s Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.